Observing newly diagnosed marginal zone lymphoma patients
A Prospective, Multi-center, Cohort Study in Newly Diagnosed Marginal Zone B-cell Lymphoma
This study looks at newly diagnosed marginal zone lymphoma patients to see how the disease behaves and how different treatments work for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06449885 on ClinicalTrials.gov |
What this trial studies
This observational cohort study focuses on patients who have been newly diagnosed with marginal zone lymphoma (MZL) within the last six months. It aims to describe the clinical features, diagnosis, treatment status, disease progression, and primary outcomes of various MZL subtypes. The study will also evaluate the efficacy and safety of different treatment modalities while collecting biological samples for further analysis. By gathering data from multiple centers, the study seeks to clarify the optimal treatment pathways for MZL.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been newly diagnosed with marginal zone lymphoma and have not yet received any anti-tumor therapy.
Not a fit: Patients with HIV infection or those unable to attend regular follow-ups may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients with marginal zone lymphoma.
How similar studies have performed: While there have been studies on marginal zone lymphoma, this specific cohort approach to observe various treatment modalities is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age≥ 18 years old; Male or female. * Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors). * Willing to provide biological samples required for the study, including blood samples and tumor tissue. * Voluntarily join this study and sign the informed consent form. * Willing to accept long-term follow-up. Exclusion Criteria: * Patients with HIV infection. * Those who cannot come to the hospital regularly for follow-up. * Those with comorbidities and speech impairment.
Where this trial is running
Shanghai, Shanghai Municipality
- Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Rong Tao, M.D
- Email: rtao@shca.org.cn
- Phone: 86-21-64175590
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.